Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) fell 0.8% during mid-day trading on Monday . The stock traded as low as $10.92 and last traded at $10.98, with a volume of 165,524 shares traded. The stock had previously closed at $11.07.

Several brokerages have recently issued reports on SCMP. Guggenheim reaffirmed a “buy” rating and issued a $29.00 target price on shares of Sucampo Pharmaceuticals in a report on Wednesday, May 4th. Mizuho reaffirmed a “buy” rating on shares of Sucampo Pharmaceuticals in a report on Monday, July 11th. Maxim Group reduced their target price on Sucampo Pharmaceuticals from $26.00 to $17.00 and set a “buy” rating on the stock in a report on Monday, August 1st. Zacks Investment Research raised Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, August 8th. Finally, Jefferies Group reduced their target price on Sucampo Pharmaceuticals from $16.00 to $14.00 and set a “hold” rating on the stock in a report on Thursday, August 4th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $19.67.

The company has a market cap of $470.48 million and a P/E ratio of 38.56. The firm has a 50 day moving average of $11.54 and a 200 day moving average of $11.49.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.01. The firm had revenue of $52 million for the quarter, compared to analysts’ expectations of $48.33 million. The company’s revenue was up 49.1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.21 earnings per share. Equities analysts predict that Sucampo Pharmaceuticals Inc. will post $1.02 EPS for the current fiscal year.

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.